- ICH GCP
- EU Kliniske forsøgsregister
Seneste forsøg
EudraCT Number: 2007-000187-25 | Sponsor Protocol Number: AC4108123 | Start Date: | |||||||||||
Sponsor Name: GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled dose... | |||||||||||||
Medical condition: Chronic Obstructive Pumonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008287-28 | Sponsor Protocol Number: ALI-FRA-0030-I | Start Date: | |||||||||||
Sponsor Name: University Hospital Erlangen | |||||||||||||
Full Title: Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes | |||||||||||||
Medical condition: Patients with prediabetes (either impaired glucose tolerance or imparied fasting glucose) and no obvious diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002636-82 | Sponsor Protocol Number: OTL-200-07 | Start Date: | |||||||||||
Sponsor Name: Orchard Therapeutics (Europe) Limited | |||||||||||||
Full Title: An open label, non-randomised trial to evaluate the safety and efficacy of a single infusion of OTL-200 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD) | |||||||||||||
Medical condition: Metachromatic Leukodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005914-33 | Sponsor Protocol Number: VX21-445-125 | Start Date: | |||||||||||
Sponsor Name: Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3 Open-label Study Evaluating the Longterm Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects With Non-F508del CFTR Genotypes | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) SE (Ongoing) NO (Ongoing) NL (Ongoing) IT (Ongoing) BE (Ongoing) AT (Ongoing) PT (Ongoing) PL (Ongoing) HU (Ongoing) CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002420-15 | Sponsor Protocol Number: RIC2006 | Start Date: | ||||||
Sponsor Name: Universität Leipzig | ||||||||
Full Title: Phase II-Studie zur Effizienz der vorzeitigen Reduktion von CSA/MMF bei fallendem linienspezifischen Chimärismus nach allogener Stammzelltransplantation nach Konditionierung mit low-dose TBI/Flud... | ||||||||
Medical condition: Effizienz der vorzeitigen Reduktion von CSA/MMF bei fallendem linienspezifischen Chimärismus nach allogener Stammzelltransplantation nach Konditionierung mit low-dose TBI/Fludarabin bei älteren ... | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001496-48 | Sponsor Protocol Number: OTI179 | Start Date: | ||||||
Sponsor Name: BIOCODEX | ||||||||
Full Title: Evaluation de l'efficacité d’une solution de chlorhydrate de lidocaïne 1% et de phénazone 4% en gouttes auriculaires (Otipax®) dans l’otite moyenne aiguë congestive de l’enfant Etude clinique ouv... | ||||||||
Medical condition: Congestive acute otitis media of children | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||
Trial protocol: FR (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005455-37 | Sponsor Protocol Number: 178-CL-207 | Start Date: | ||||||||||||||||
Sponsor Name: Astellas Pharma Global Development Inc. | ||||||||||||||||||
Full Title: A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron P... | ||||||||||||||||||
Medical condition: Neurogenic detrusor overactivity (NDO) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Ongoing) DK (Trial now transitioned) PL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004583-40 | Sponsor Protocol Number: 101010 | Start Date: | |||||||||||
Sponsor Name: Universitaetsklinikum Muenster | |||||||||||||
Full Title: A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML. | |||||||||||||
Medical condition: The disease under investigation is newly diagnosed Acute Myeloid Leucemia (AML) in elderly patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002936-55 | Sponsor Protocol Number: MSC-EB_2020 | Start Date: | ||||||
Sponsor Name: Masarykova univerzita | ||||||||
Full Title: Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells in Patients with Epidermolysis Bullosa: Clinical Trial Phase I/II | ||||||||
Medical condition: Epidermolysis bullosa congenita | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||
Trial protocol: CZ (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002482-17 | Sponsor Protocol Number: TAK-935-3003 | Start Date: | ||||||||||||||||
Sponsor Name: Takeda Development Center Americas, Inc | ||||||||||||||||||
Full Title: A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or ... | ||||||||||||||||||
Medical condition: Dravet Syndrome (DS) Lennox-Gastaut Syndrome (LGS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Ongoing) ES (Ongoing) NL (Ongoing) HU (Ongoing) FR (Ongoing) GR (Ongoing) IT (Ongoing) LV (Ongoing) PL (Ongoing) Outside EU/EEA | ||||||||||||||||||
Trial results: (No results available) |